Home » Stocks » LCTX

Lineage Cell Therapeutics, Inc. (LCTX)

Stock Price: $2.66 USD -0.02 (-0.75%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 431.30M
Revenue (ttm) 1.70M
Net Income (ttm) -13.67M
Shares Out 158.73M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $2.66
Previous Close $2.68
Change ($) -0.02
Change (%) -0.75%
Day's Open 2.69
Day's Range 2.63 - 2.72
Day's Volume 954,737
52-Week Range 0.79 - 3.13

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

4 days ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

1 week ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell th...

3 weeks ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--OPC1 Clinical Update

1 month ago - Business Wire

Lineage Cell Therapeutics Inc (NYSE: LCTX) has granted an exclusive option to Amasa Therapeutics Inc to acquire an exclusive, royalty-bearing license to use its HyStem technology to develop and commerci...

1 month ago - Benzinga

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...

1 month ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CFO--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

1 month ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...

1 month ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...

1 month ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...

1 month ago - Business Wire

The company reported great news from a clinical study of its experimental cell therapy for treating eye disease.

1 month ago - The Motley Fool

Lineage Cell Therapeutics Inc (NYSE: LCTX) has announced that restoration of retinal tissue was observed in two additional patients enrolled in the Phase 1/2a study of its lead product candidate, OpRege...

1 month ago - Benzinga

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...

1 month ago - Business Wire

Lineage Cell (LCTX) delivered earnings and revenue surprises of -50.00% and -63.46%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...

2 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for ser...

2 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...

2 months ago - Business Wire

Lineage Cell Therapeutics Inc (NYSE: LCTX) has updated interim results from its ongoing Phase 1/2a study of its lead product candidate, OpRegen, for dry age-related macular degeneration (AMD) with geogr...

2 months ago - Benzinga

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet...

2 months ago - Business Wire

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...

2 months ago - Business Wire

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other stocks mentioned: APTX, BLRX, CYCN, PTN
3 months ago - PennyStocks

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for ser...

3 months ago - Business Wire

The company announced a license agreement.

3 months ago - The Motley Fool

Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into a worldwide license and development collaboration agreement with a privately-held Immunomic Therapeutics Inc (ITI) to manufacture and develop ...

3 months ago - Benzinga

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CancerVaccines--VAC/Immunomic Strategic Alliance

3 months ago - Business Wire

ROCKVILLE, Md. & CARLSBAD, Calif.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platfo...

3 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet...

3 months ago - Business Wire

Under a named patient compassionate use approval by the Israeli Ministry of Health, Lineage Cell Therapeutics Inc's (NYSE: LCTX) OpRegen has been used to treat a patient suffering from adult-onset vitel...

3 months ago - Benzinga

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for ser...

3 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious med...

4 months ago - Business Wire

Lineage Cell (LCTX) delivered earnings and revenue surprises of 120.00% and -73.57%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

4 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

4 months ago - Business Wire

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

4 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

5 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CIRM--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet m...

5 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CIRM--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet m...

5 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to address u...

6 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

6 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

6 months ago - Business Wire

Investors need to pay close attention to Lineage Cell Therapeutics (LCTX) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for serious...

7 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

7 months ago - Business Wire

Lineage Cell Therapeutics, Inc. is a clinical-stage biotech company focused on developing therapeutics for degenerative retinal diseases, demyelination-related neurological conditions, and cancer-relate...

8 months ago - Seeking Alpha

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #DryAMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for seri...

8 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical...

8 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for serious...

8 months ago - Business Wire

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute sp... [Read more...]

Industry
Biotechnology
Founded
1990
CEO
Brian Culley
Employees
49
Stock Exchange
NYSEAMERICAN
Ticker Symbol
LCTX
Full Company Profile

Financial Performance

In 2020, LCTX's revenue was $1.83 million, a decrease of -48.05% compared to the previous year's $3.52 million. Losses were -$20.65 million, 76.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for LCTX stock is "Buy." The 12-month stock price forecast is 5.33, which is an increase of 100.38% from the latest price.

Price Target
$5.33
(100.38% upside)
Analyst Consensus: Buy